NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $1.99 billion. The enterprise value is $1.79 billion.
Important Dates
The next estimated earnings date is Thursday, July 23, 2026, before market open.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 115.82 million shares outstanding. The number of shares has increased by 3.55% in one year.
| Current Share Class | 115.82M |
| Shares Outstanding | 115.82M |
| Shares Change (YoY) | +3.55% |
| Shares Change (QoQ) | +1.70% |
| Owned by Insiders (%) | 8.63% |
| Owned by Institutions (%) | 76.86% |
| Float | 95.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.95 |
| Forward PS | 2.78 |
| PB Ratio | 6.01 |
| P/TBV Ratio | 6.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.90, with a Debt / Equity ratio of 0.71.
| Current Ratio | 2.90 |
| Quick Ratio | 2.66 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.18 |
Financial Efficiency
Return on equity (ROE) is -49.96% and return on invested capital (ROIC) is -131.11%.
| Return on Equity (ROE) | -49.96% |
| Return on Assets (ROA) | -11.06% |
| Return on Invested Capital (ROIC) | -131.11% |
| Return on Capital Employed (ROCE) | -31.59% |
| Weighted Average Cost of Capital (WACC) | 9.04% |
| Revenue Per Employee | $420,196 |
| Profits Per Employee | -$107,817 |
| Employee Count | 1,605 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 3.99 |
Taxes
| Income Tax | -2.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.63% in the last 52 weeks. The beta is 0.92, so NovoCure's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | +2.63% |
| 50-Day Moving Average | 14.50 |
| 200-Day Moving Average | 13.13 |
| Relative Strength Index (RSI) | 54.72 |
| Average Volume (20 Days) | 1,581,801 |
Short Selling Information
The latest short interest is 8.54 million, so 7.37% of the outstanding shares have been sold short.
| Short Interest | 8.54M |
| Short Previous Month | 6.97M |
| Short % of Shares Out | 7.37% |
| Short % of Float | 8.96% |
| Short Ratio (days to cover) | 4.54 |
Income Statement
In the last 12 months, NovoCure had revenue of $674.41 million and -$173.05 million in losses. Loss per share was -$1.54.
| Revenue | 674.41M |
| Gross Profit | 508.84M |
| Operating Income | -180.15M |
| Pretax Income | -175.21M |
| Net Income | -173.05M |
| EBITDA | -166.22M |
| EBIT | -180.15M |
| Loss Per Share | -$1.54 |
Full Income StatementBalance Sheet
The company has $432.00 million in cash and $234.94 million in debt, with a net cash position of $197.06 million or $1.70 per share.
| Cash & Cash Equivalents | 432.00M |
| Total Debt | 234.94M |
| Net Cash | 197.06M |
| Net Cash Per Share | $1.70 |
| Equity (Book Value) | 330.72M |
| Book Value Per Share | 2.86 |
| Working Capital | 414.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$26.88 million and capital expenditures -$21.19 million, giving a free cash flow of -$48.07 million.
| Operating Cash Flow | -26.88M |
| Capital Expenditures | -21.19M |
| Depreciation & Amortization | 13.93M |
| Net Borrowing | -460.97M |
| Free Cash Flow | -48.07M |
| FCF Per Share | -$0.42 |
Full Cash Flow StatementMargins
Gross margin is 75.45%, with operating and profit margins of -26.71% and -25.66%.
| Gross Margin | 75.45% |
| Operating Margin | -26.71% |
| Pretax Margin | -25.98% |
| Profit Margin | -25.66% |
| EBITDA Margin | -24.65% |
| EBIT Margin | -26.71% |
| FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.55% |
| Shareholder Yield | -3.55% |
| Earnings Yield | -8.71% |
| FCF Yield | -2.42% |
Analyst Forecast
The average price target for NovoCure is $26.29, which is 53.21% higher than the current price. The consensus rating is "Buy".
| Price Target | $26.29 |
| Price Target Difference | 53.21% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 13.07% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.37 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.37 |
| Piotroski F-Score | 3 |
